ConsoneAI is at the forefront of the TechBio sector, focusing on enhancing drug development and chemical safety through advanced computational models and artificial intelligence. The company has developed a comprehensive toxicity database that includes over 80,000 chemical compounds, integrating data from both animal and human studies. Their innovative platform employs deep learning techniques to create bespoke models tailored to the chemical similarities of each compound, allowing for precise predictions of toxicity at the organism level. This approach not only reduces the reliance on traditional animal testing but also aligns with ethical standards and regulatory guidelines, supporting the industry's commitment to the 3Rs: Reduce, Replace, and Refine.

The services offered by ConsoneAI, particularly their product DioScor, aim to streamline the drug development process by predicting patient outcomes from preclinical to clinical stages. By identifying potential safety issues early in the development timeline, ConsoneAI enhances the safety and efficacy of drugs, thereby improving the overall success rates of drug candidates. Their technology facilitates compliance with global regulatory requirements and supports Investigational New Drug (IND) applications with robust toxicity data. Ultimately, ConsoneAI's predictive capabilities not only accelerate the development timeline but also reduce costs associated with late-stage failures, making the drug development process more efficient and effective.

United Kingdom

Consone AI a disruptive technology platform targeting how decisions are made in the drug development process. Accelerating new medicines to market, reducing cost, reducing preclinical toxic trials,  time and environmental footprints. The Consone AI platform will empower user decision making by successfully predicting toxicological effects and viability of new drugs.

ConsoneAI

Company Details